Psychiatry

#Bipolar #Johnson & Johnson #Neuroscience #Phase III trial #Psychiatry

Phase III study supports lumateperone use in bipolar mania

Johnson & Johnson has announced positive topline results from a Phase III study evaluating Caplyta (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder.   The study met its primary endpoint, with Caplyta demonstrating a statistically significant and rapid… Read More

#News

Neuroscience Parkinson's disease
#Autobahn Therapeutics #Bipolar #Neuroscience #Phase II trial #Psychiatry

Bipolar treatment leads to rapid antidepressant effects

A treatment for patients with bipolar I or bipolar II depression has demonstrated durable antidepressant effects, results show. Elunetirom, developed by Autobahn Therapeutics, is a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist. In the Phase II AMPLIFY-BD trial, elunetirom was evaluated as an adjunctive… Read More

#News

Neuronal network
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

eBook: What’s new in neuroscience drug discovery?

The global neuroscience market has grown significantly in the last 10 years, driven predominantly by an ageing population and increasing cases of neurodegenerative diseases like Alzheimer’s disease (AD). The neuroscience market size was estimated at $44.65 billion in 2023 and is projected to reach $65.22 billion by 2030,… Read More

#News

DDW Neuroscience book cover
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

What’s new in neuroscience drug discovery?

This eBook, sponsored by Emulate, explores the latest developments in our understanding of neuroscience and the new therapies coming to market, spanning neurodegenerative diseases, genetic disorders, and psychiatry.

#DDW eBooks #Intelligence

Antibiotics
#Antibiotics #Mental health #Psychiatry #Schizophrenia

Antibiotic doxycycline shown to reduce schizophrenia risk

A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research suggests.  Experts found that patients of adolescent mental health services who were treated with the antibiotic doxycycline were significantly less likely to go on to develop schizophrenia in adulthood compared… Read More

#News

Patient speaking to psychiatrist
#Clinical trials #Mental health #Psychiatry #UK

First NHS-embedded clinical trial site for mental health launches

The UK’s first fully NHS-embedded commercial research for brain and mental health conditions has been launched by Clerkenwell Health.   Developed in partnership with Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust, the initiative aims to set a new standard for how trials are delivered in the… Read More

#News

#AbbVie #Major depressive disorder #Mergers and acquisitions #Psychedelics #Psychiatry

AbbVie acquires psychedelic for major depressive disorder

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion.  Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and durable antidepressant effects.  … Read More

#Business & Investment #News

Degeneration of dopaminergic neuron in Parkinson's disease
#Depression #Drug repurposing #Parkinson's #Psychiatry #Treatment-resistant depression #University of Oxford

Dopamine-boosting Parkinson’s drug treats depression

A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.  In the largest clinical trial to date, pramipexole was found to be substantially more effective than a… Read More

#Editor's Choice #News

Magic Mushrooms in laboratory. Psilocybin science and research.
#Alcohol Use Disorder #Mental health #Oncology #Psilocybin #Psychedelics #Psychiatry

Findings support positive mental health benefits of psychedelics

One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests.   A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder.  In the… Read More

#News

The microbiome
#Gut microbiome #Mental health #Microbiome #Psychiatry

Can the gut microbiome unlock new therapeutics in mental health?

Janet Sasso and Rumiana Tenchov, Information Scientists at CAS, discuss the relationship between the gut microbiome and mental health, reporting on topics that CAS has explored over the recent years. The gut-brain axis (GBA), a signalling pathway connecting the gastrointestinal tract and the central nervous system, has increasingly been found… Read More

#Exclusive Content

Neuron
#Neurology #Neuroscience #Precision medicine #Psychiatry #Webinar

Watch now! DDW Neuroscience Showcase

In this free online event hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel discussion looking at the use of new drug discovery… Read More

#News

Neurons
#Bipolar #Neuroscience #Psychiatry #Society for Neuroscience #Walsh Research Institute

Breakthroughs in bipolar disorder announced at Neuroscience 2024

A Walsh Research Institute scientist presented an advanced theory of bipolar disorder at the annual meeting of the Society for Neuroscience, Neuroscience 2024. After a multi-year investigation of recent neuroscience advances, Dr William Walsh believes he has resolved many unknowns that have puzzled researchers for a… Read More

#News #Trending News

Neurons in the brain
#Neurocrine Biosciences #Neuroscience #Phase II trial #Psychiatry #Schizophrenia

Muscarinic M4 selective agonist shows promise in schizophrenia

Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia. NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication. The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for… Read More

#News

Former soldier suffering from PTSD
#FDA #MDMA #Psychiatry #PTSD

FDA urged to approve MDMA-assisted therapy for PTSD

Two veteran advocacy organisations, Reason for Hope and the Veteran Mental Health Leadership Coalition, have issued a joint statement urging the US Food and Drug Administration (FDA) to approve MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Last month, an FDA Advisory Committee recommended against approval, with only two out of… Read More

#News #Regulatory

#Antidepressants #Neurology #Neuropsychiatric disorders #Neuroscience #Psychedelics #Psychiatry

Reshaping neuropsychiatry

Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More

#Exclusive Content

Traumatic brain injury
#Brain injury #Neuroscience #Plant-based #Psychiatry #PTSD #Stanford University

Plant-based psychoactive drug treats traumatic brain injury

New research has found that plant-based psychoactive drug ibogaine improved depression, anxiety and functioning among veterans with traumatic brain injuries (TBI). TBI from head trauma or blast explosions are a leading cause of post-traumatic stress disorder (PTSD), anxiety, depression and suicide among veterans. Stanford… Read More

#News #Trending News